Prostate cancer drug gets Fast Track designation

The FDA has awarded Fast Track designation to Dendreon for its prostate cancer drug Provenge. Results from the phase III study show that Provenge could improve the survival rates of men with asymptomatic, metastatic, androgen-independent prostate cancer. Each year prostate cancer kills over 30,000 men.

- read this press release for more